118 related articles for article (PubMed ID: 35970044)
1. Induction of chronic lymphocytic leukemia-like disease in STYK1/NOK transgenic mice.
Yang Y; Liu L; Tucker HO
Biochem Biophys Res Commun; 2022 Oct; 626():51-57. PubMed ID: 35970044
[TBL] [Abstract][Full Text] [Related]
2. The malignant transformation potential of the oncogene STYK1/NOK at early lymphocyte development in transgenic mice.
Yang Y; Liu L; Tucker HO
Biochem Biophys Rep; 2024 Jul; 38():101709. PubMed ID: 38638675
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic relevance of overexpressed serine threonine tyrosine kinase/novel oncogene with kinase domain (STYK1/ NOK) mRNA in colorectal cancer.
Orang AV; Safaralizadeh R; Hosseinpour Feizi MA; Somi MH
Asian Pac J Cancer Prev; 2014; 15(16):6685-9. PubMed ID: 25169509
[TBL] [Abstract][Full Text] [Related]
4. A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment.
Kimbro KS; Duschene K; Willard M; Moore JA; Freeman S
Mol Biol Rep; 2008 Mar; 35(1):23-7. PubMed ID: 17415682
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of serine threonine tyrosine kinase 1/novel oncogene with kinase domain mRNA in patients with acute leukemia.
Kondoh T; Kobayashi D; Tsuji N; Kuribayashi K; Watanabe N
Exp Hematol; 2009 Jul; 37(7):824-30. PubMed ID: 19409952
[TBL] [Abstract][Full Text] [Related]
6. STYK1/NOK affects cell cycle late mitosis and directly interacts with anaphase-promoting complex activator CDH1.
Zeng SL; Patel SS; Lv MQ; Zhu D; Shen WH; Liu L
Heliyon; 2022 Dec; 8(12):e12058. PubMed ID: 36506394
[TBL] [Abstract][Full Text] [Related]
7. NOK/STYK1 promotes the genesis and remodeling of blood and lymphatic vessels during tumor progression.
Liu Y; Li T; Hu D; Zhang S
Biochem Biophys Res Commun; 2016 Sep; 478(1):254-259. PubMed ID: 27444381
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of GLUT3 impairs STYK1/NOK-mediated metabolic reprogramming and proliferation in NIH-3T3 cells.
Shi W; Fu Y; Wang Y
Oncol Lett; 2021 Jul; 22(1):527. PubMed ID: 34055092
[TBL] [Abstract][Full Text] [Related]
9. NOK mediated mitogenic signaling is altered by P203L and V395I mutations.
Hou SQ; Liu L
Front Biosci (Landmark Ed); 2015 Jun; 20(7):1179-89. PubMed ID: 25961552
[TBL] [Abstract][Full Text] [Related]
10. Styk1 expression is a hallmark of murine NK cells and other NK1.1
Fauteux-Daniel S; Faure F; Marotel M; Geary C; Daussy C; Sun JC; Walzer T
Eur J Immunol; 2019 May; 49(5):677-685. PubMed ID: 30690705
[TBL] [Abstract][Full Text] [Related]
11. STYK1 promotes autophagy through enhancing the assembly of autophagy-specific class III phosphatidylinositol 3-kinase complex I.
Zhou C; Qian X; Hu M; Zhang R; Liu N; Huang Y; Yang J; Zhang J; Bai H; Yang Y; Wang Y; Ali D; Michalak M; Chen XZ; Tang J
Autophagy; 2020 Oct; 16(10):1786-1806. PubMed ID: 31696776
[TBL] [Abstract][Full Text] [Related]
12. NOK/STYK1 has a strong tendency towards forming aggregates and colocalises with epidermal growth factor receptor in endosomes.
Ding X; Jiang QB; Li R; Chen S; Zhang S
Biochem Biophys Res Commun; 2012 May; 421(3):468-73. PubMed ID: 22516751
[TBL] [Abstract][Full Text] [Related]
13. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression.
Santanam U; Zanesi N; Efanov A; Costinean S; Palamarchuk A; Hagan JP; Volinia S; Alder H; Rassenti L; Kipps T; Croce CM; Pekarsky Y
Proc Natl Acad Sci U S A; 2010 Jul; 107(27):12210-5. PubMed ID: 20566844
[TBL] [Abstract][Full Text] [Related]
14. The
Perez-Chacon G; Zapata JM
Front Immunol; 2021; 12():627602. PubMed ID: 33912159
[TBL] [Abstract][Full Text] [Related]
15. Significance of serine threonine tyrosine kinase 1 as a drug resistance factor and therapeutic predictor in acute leukemia.
Nirasawa S; Kobayashi D; Kondoh T; Kuribayashi K; Tanaka M; Yanagihara N; Watanabe N
Int J Oncol; 2014 Nov; 45(5):1867-74. PubMed ID: 25190507
[TBL] [Abstract][Full Text] [Related]
16. STYK1/NOK correlates with ferroptosis in non-small cell lung carcinoma.
Lai Y; Zhang Z; Li J; Li W; Huang Z; Zhang C; Li X; Zhao J
Biochem Biophys Res Commun; 2019 Nov; 519(4):659-666. PubMed ID: 31542233
[TBL] [Abstract][Full Text] [Related]
17. NOK/STYK1 interacts with GSK-3β and mediates Ser9 phosphorylation through activated Akt.
Li J; Wu F; Sheng F; Li YJ; Jin D; Ding X; Zhang S
FEBS Lett; 2012 Nov; 586(21):3787-92. PubMed ID: 23010592
[TBL] [Abstract][Full Text] [Related]
18. Styk1 is specifically expressed in NK1.1
Wilharm A; Sandrock I; Marotel M; Demera A; Naumann R; Walzer T; Prinz I
Eur J Immunol; 2019 May; 49(5):686-693. PubMed ID: 30758858
[TBL] [Abstract][Full Text] [Related]
19. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.
DiLillo DJ; Weinberg JB; Yoshizaki A; Horikawa M; Bryant JM; Iwata Y; Matsushita T; Matta KM; Chen Y; Venturi GM; Russo G; Gockerman JP; Moore JO; Diehl LF; Volkheimer AD; Friedman DR; Lanasa MC; Hall RP; Tedder TF
Leukemia; 2013 Jan; 27(1):170-82. PubMed ID: 22713648
[TBL] [Abstract][Full Text] [Related]
20. Early generated B1 B cells with restricted BCRs become chronic lymphocytic leukemia with continued c-Myc and low Bmf expression.
Hayakawa K; Formica AM; Brill-Dashoff J; Shinton SA; Ichikawa D; Zhou Y; Morse HC; Hardy RR
J Exp Med; 2016 Dec; 213(13):3007-3024. PubMed ID: 27899442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
